Biological treatment service for rabies ceases, leading to fears for people exposed to virus
HSE
official has said.
Until the start of this month, a service operated out of Cherry Orchard Hospital, Dublin, was responsible for the assessment of patients and delivery of 'critical' biologics to patients with acute post-exposure treatment of rabies, diphtheria and botulinum.
On July 3rd,
Colm Henry
, chief clinical officer at the HSE, wrote to the country's regional executive officers and regional clinical directors following the retirement of the doctor who ran the Cherry Orchard service.
Following his retirement on July 4th, the service would cease to operate, Dr Henry said.
READ MORE
'While this service had never been commissioned as a national service, it had, in effect, provided advice and treatment on management of potentially or actually exposed patients for many years from all over the country,' his letter said.
Dr Henry said in light of the 'importance' of this service, the National Health Protection Office has been working with key partners and stakeholders to support implementation of a new regional service model.
'There are risks, while these discussions are taking place, of gaps in service and therefore potential for a person with a rabies prone exposure being missed, lost to follow up or inappropriately managed,' his letter said.
Dr Henry requested the regional executive officers to work with stakeholders and structures to 'ensure provision of service and further development of same to address issues and risks identified'.
According to his letter, there are areas in which there has been consensus in relation to the establishment of regional services, including a proposed role for emergency departments, which will see and assess new presentations.
However, he also highlighted a number of 'issues requiring further consideration/agreement' such as the provision of out-of-hours services or infectious diseases on-call hours for weekends and bank holidays.
In a statement, a spokesman for the HSE said the service for rabies exposure was 'formally reorganised on a regional footprint to better meet the needs of local populations'.
The spokesman said a working group will work with implementation committees to 'mitigate any risk relating to access to assessment and care for patients, potentially created by the standing down of a previously available service, which had been in place for many years'.
Rabies is a rare viral infection, but a person's risk of contracting it becomes significant if they travel to parts of the world where rabies is common in land-based animals.
If a person is exposed to an animal in such countries, they must immediately seek medical advice and report this contact to a local hospital or clinic to enable assessment.
Diphtheria is an acute bacterial disease, mainly affecting the respiratory system. The most recent case of diphtheria in Ireland was in 2016.
Botulism is a rare but life-threatening condition caused by toxins produced by Clostridium botulinum bacteria. There has been a surge in botulism poisonings in England over the past six weeks.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Daily Mirror
an hour ago
- Irish Daily Mirror
HSE paid supplier €723,000 twice in 2021 and has not recovered overpayment
The HSE paid a supplier €723,000 twice and has not recovered the overpayment according to the State auditor. The double payment was made by two different areas of the HSE on separate financial systems operating in December 2021, which was not cross-checked. The Comptroller and Auditor General Seamus McCarthy said the HSE disclosed the payment and set out actions to avoid such a situation in the future. "The HSE acknowledges there were weaknesses in controls, particularly, in relation to appropriate goods receipting protocols," Mr McCarthy said in an assessment attached to the HSE's annual report and financial statements for 2024. "The statement on internal control sets out the actions taken by the Health Service Executive to avoid similar circumstances recurring in the future." He said a single integrated financial system, which was due to go live at the start of this month, would "significantly reduce the risk of this kind of overpayment occurring in the future". Mr McCarthy also highlighted that €4.1 million due to the HSE was lost last year by missing deadlines by which it could claim charges for patients covered by a health insurer. A memorandum of agreement with the health insurer in 2016 sees the HSE paid 70 per cent of its charges for a patient stay, on account, if it makes its submission and validation within a 12-month period of a fully completed claim. If it does not meet that deadline, it must pay for all of the costs. "For a sample of eight hospitals examined on audit, it was noted that losses incurred in 2024 as a result of delays in submitting completed claims amounted to €2 million," Mr McCarthy said. "The Executive estimates that losses for the remaining hospitals it manages were €2.1 million, resulting in an estimated total loss of €4.1 million for 2024." The HSE's annual report indicated there was a 10 per cent reduction in the number of people waiting on trolleys in emergency departments last year. Over 108,000 people were recorded on trolleys in emergency departments last year, amid an 8 per cent increase in the total number of people attending and a rise of 7 per cent in admissions to emergency departments. HSE chief executive Bernard Gloster said one of the most "challenging" aspects for the HSE was wait times for healthcare, and said tackling "unacceptably long" waits in emergency departments was an area of focus. HSE CEO Bernard Gloster (Image: Gareth Chaney/Collins) The HSE annual report for 2024 analyses the health service's performance and health trends among Irish people. "Addressing waiting lists for scheduled care and unacceptably long waits in emergency departments (EDs) remains a priority focus area, especially for older people and those with complex needs," Mr Gloster said in the foreword. "My plan for 2025 is to continue to bring trolley numbers down and to improve how our health and social care system works across seven days to allow consistent access to care." Requests for assessments of need for children spiked by 26 per cent last year compared to a year previous, and were 33 per cent above expected demand in 2024. There were 8,400 such requests in 2023 and more than 10,600 in 2024, in figures which had previously been shared by Children's Minister Norma Foley in the Dail. Norma Foley (Image: Gareth Chaney/Collins Photos) Although there was a slight uptake on the measles, mumps, rubella (MMR) vaccine compared to the previous year, the 89.9 per cent figure was below the target for 2024. The chairman of the HSE's board, Ciaran Devane, said in an introductory statement to the report that Ireland's population is ageing "faster than that of any other country in the EU". Since 2015, the number of people aged 65 years and over has increased by 37 per cent. Although life expectancy in Ireland, at 82.6 years, is ahead of the EU average, the burden of cancer is higher and accounts for a quarter of all deaths of those aged over 65. Mr Gloster, who is to step down from his role in March 2026, said 2024 was a year of "real progress". "We reduced the number of people waiting on trolleys by over 10 per cent, expanded community services and improved access to scheduled care with an additional 24,000 patients seen within target timeframes. "Our focus in 2025 will be to build on this momentum, improve patient flow and continue to reform how care is delivered across seven days." Subscribe to our newsletter for the latest news from the Irish Mirror direct to your inbox: Sign up here.
Irish Independent
an hour ago
- Irish Independent
HSE paid supplier €723k twice and has not clawed back overpayment
The double payment was made by two different areas of the HSE on separate financial systems operating in December 2021, which was not cross checked. The Comptroller and Auditor General Seamus McCarthy said the HSE disclosed the payment and set out actions to avoid such a situation in the future. "The HSE acknowledges there were weaknesses in controls, particularly, in relation to appropriate goods receipting protocols," Mr McCarthy said in an assessment attached to the HSE's annual report and financial statements for 2024. "The statement on internal control sets out the actions taken by the Health Service Executive to avoid similar circumstances recurring in the future." He said a single integrated financial system, which was due to go live at the start of this month, would "significantly reduce the risk of this kind of overpayment occurring in the future". Mr McCarthy also highlighted that €4.1m euro due to the HSE was lost last year by missing deadlines by which it could claim charges for patients covered by a health insurer. A memorandum of agreement with the health insurer in 2016 sees the HSE paid 70pc of its charges for a patient stay, on account, if it makes its submission and validation within a 12-month period of a fully completed claim. If it does not meet that deadline, it must pay for all of the costs. "For a sample of eight hospitals examined on audit, it was noted that losses incurred in 2024 as a result of delays in submitting completed claims amounted to two million euro," Mr McCarthy said. "The Executive estimates that losses for the remaining hospitals it manages were €2.1m, resulting in an estimated total loss of €4.1m for 2024." The HSE's annual report indicated there was a 10pc reduction in the number of people waiting on trolleys in emergency departments last year. Over 108,000 people were recorded on trolleys in emergency departments last year, amid an 8pc increase in the total number of people attending and a rise of 7pc in admissions to emergency departments. HSE chief executive Bernard Gloster said one of the most "challenging" aspects for the HSE was wait times for healthcare, and said tackling "unacceptably long" waits in emergency departments was an area of focus. The HSE annual report for 2024 analyses the health service's performance and health trends among Irish people. "Addressing waiting lists for scheduled care and unacceptably long waits in emergency departments (EDs) remains a priority focus area, especially for older people and those with complex needs," Mr Gloster said in the foreword. "My plan for 2025 is to continue to bring trolley numbers down and to improve how our health and social care system works across seven days to allow consistent access to care." Requests for assessments of need for children spiked by 26pc last year compared to a year previous, and were 33pc above expected demand in 2024. There were 8,400 such requests in 2023 and more than 10,600 in 2024, in figures which had previously been shared by Children's Minister Norma Foley in the Dail. Although there was a slight uptake on the measles, mumps, rubella (MMR) vaccine compared to the previous year, the 89.9% figure was below the target for 2024. The chairman of the HSE's board, Ciaran Devane, said in an introductory statement to the report that Ireland's population is ageing "faster than that of any other country in the EU". Since 2015, the number of people aged 65 years and over has increased by 37pc. Although life expectancy in Ireland, at 82.6 years, is ahead of the EU average, the burden of cancer is higher and accounts for a quarter of all deaths of those aged over 65. Mr Gloster, who is to step down from his role in March 2026, said 2024 was a year of "real progress". "We reduced the number of people waiting on trolleys by over 10pc, expanded community services and improved access to scheduled care with an additional 24,000 patients seen within target timeframes. "Our focus in 2025 will be to build on this momentum, improve patient flow and continue to reform how care is delivered across seven days."
Irish Times
3 hours ago
- Irish Times
HSE paid €720,000 invoice twice using different systems, audit finds
Two separate parts of the HSE , which operated different financial systems, paid a supplier more than €700,000 for the same invoice, new accounts published by the health service show. In a note on the accounts, the State's financial watchdog, the Comptroller and Auditor General maintains the HSE has not recovered the overpayment. The accounts also show that what is described as an 'asset', constructed in 2009 at a cost of €1.4 million but never used for its intended purposes, had been written off last year. The accounts say the cost of the write off was €800,000. The annual report and accounts for 2024 also reveal that about €4 million in payments due from the health insurance industry in respect of subscribers treated in HSE facilities was written off due to delays in submitting bills. The report says the risk of bad debts 'is most relevant' in relation to claims from one health insurer, which is not identified. The report says the HSE entered into a memorandum of agreement with a health insurer in 2016 in relation to accommodation charges for patients with private health insurance. 'The arrangement entitles the Executive to be paid 70 per cent of its charges, on account, pending the submission and validation within a 12-month period of a fully completed claim. Failure to meet the submission deadline results in forfeiture of the full value (100 per cent) of the claim.' [ Listeriosis outbreak 'unusual' as ready meals must be cooked, and bacteria is sensitive to heat, professor says Opens in new window ] 'For a sample of eight hospitals examined on audit, it was noted that losses incurred in 2024 as a result of delays in submitting completed claims amounted to €2 million. The Executive estimates that losses for the remaining hospitals that it manages were €2.1 million, resulting in an estimated total loss of €4.1 million for 2024. The annual report also shows that one HSE employee received just under €700,000 in total payments including basic pay, allowances, overtime and weekend, night duty and on-call fees last year. A total of ten HSE staff were paid in excess of €500,000 overall. The report also reveals that personal protective equipment worth about €22 million and vaccines to the value of about €11 million had been written off because they had become obsolete. The report shows that the supplier who was paid twice had entered into an arrangement with the HSE in 2020 for the supply of diagnostic devices, ancillary supplies and equipment as well as information technology and support. It says the overall system 'was considered to be of significant value in monitoring the condition of Covid-19 patients in hospital settings'. Ultimately the supplier received about €15 million up to 2024. However, the report raises concerns about procurement arrangements and controls over how the money was being spent. [ Inquiry begins into historical use of anti-epileptic drug and effects on pregnant women Opens in new window ] 'The initial arrangement with the supplier was put in place without a competitive procurement process on the basis of emergency circumstances, as provided for in procurement legislation. However, the arrangement continued each year until 2024 without being regularised through an appropriate competitive tendering process. Accordingly, it represented significant non-compliant procurement over a number of years.' 'The payments to the supplier over the period 2020 to 2024 amounted to a total of €15 million. However, the terms of the procurement arrangement were not set out in a formal written contract with the supplier. In practice, the arrangement was that a number of units of the Health Service Executive were invoiced from time to time by the supplier for devices and ancillary items. This included prepayment each quarter from mid-2022 to mid-2024 for supply of a standard number of devices, to be drawn down as required by individual hospitals. The Executive did not maintain central records of the total number of units paid for. The number of devices received by hospitals, or paid for and remaining undrawn from the supplier is not known. The Executive also does not know how many of the items paid for were actually used in its hospitals.' 'The Executive discloses that as part of efforts to improve control over the receipt of goods, it identified that one invoice from the supplier to the value of €723,000 had been paid twice, in two different areas of the Executive operating at the time (in December 2021) on separate financial systems. The Executive has not recovered the overpayment from the supplier.'
